Clinical Efficacy of Neurotrophic Treatment in Stroke and Traumatic Brain Injuries

A.V. Savustyanenko


Stroke is one of the most devastating vascular diseases in the world as it is responsible for almost five million deaths per year. Almost 90 % of all strokes are ischemic and mainly due to atherosclerosis, cardiac embolism and small-vessel disease. Intracerebral or subarachnoid hemorrhage can lead to hemorrhagic stroke, which usually has the poorest prognosis. Cerebrolysin is a peptide preparation which mimics the action of a neurotrophic factor, protecting stroke-injured neurons and promoting neuroplasticity and neurogenesis. Cerebrolysin has been widely studied as a therapeutic tool for both ischemic and hemorrhagic stroke, as well as traumatic brain injury. In ischemic stroke, Cerebrolysin given as an adjuvant therapy to antiplatelet and rheologically active medication resulted in accelerated improvement in global, neurological and motor functions, cognitive performance and activities of daily living. Cerebrolysin was also safe and well tolerated when administered in patients suffering from hemorrhagic stroke. Traumatic brain injury leads to transient or chronic impairments in physical, cognitive, emotional and behavioural functions. This is associated with deficits in the recognition of basic emotions, the capacity to interpret the mental states of others, and executive functioning. Pilot clinical studies with adjuvant Cerebrolysin in the acute and postacute phases of the injury have shown faster recovery, which translates into an earlier onset of rehabilitation and shortened hospitalization time.


ischemic stroke; traumatic brain injury; neurotrophic therapy; Cerebrolysin


World Development Report. Investing in Health. — Oxford: Oxford University Press, 1993.

Bogousslavsky J. Stroke prevention by the practitioner // Cerebrovasc. Dis. 1999, 9 (Suppl. 4): 1-70.

Pendlebury S.T., Rothwell P.M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: A systematic review and meta-analysis // Lancet Neurol. 2009, 8(11): 1006-18.

Payne K.A., Huybrechts K.F., Caro J.J., Craig Green T.J., Klittic W.S. Long term cost-of-illness in stroke. An international review // Pharmacoeconomics. 2002, 20(12): 813-25.

Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2008, 117(4): e25-146.

Adams H.P. Jr., Bendixen B.H., Kappelle L.J. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment // Stroke. 1993, 24(1): 35-41.

Davis S., Lees K., Donnan G. Treating the acute stroke patient as an emergency: Current practices and future opportunities // Int. J. Clin. Pract. 2006, 60(4): 399-407.

Hacke W., Brott T., Caplan L. et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience // Neurology. 1999, 53 (Suppl. 4): S3-14.

Butcher K., Parsons M., Baird T. et al. Perfusion thresholds in acute stroke thrombolysis // Stroke. 2003, 34(9): 2159-64.

De Keyser J., Sulter G., Luiten P.G. Clinical trials with neuroprotective drugs in acute ischemic stroke // Trends Neurosci. 1999, 22(12): 535-40.

Clark W.M., Wechsler L.R., Sabounjian R.N., Schwiderski U.E. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients // Neurology. 2001, 57(9): 1595-602.

Sacco R.L., DeRosa J.T., Clarke Haley E. et al. Glycin antagonist in neuroprotection for patients with acute stroke // JAMA. 2001, 285(13): 1719-28.

Martinez Vila W., Siera P.I. Current status and perspectives of neuroprotection in ischemic stroke // Cerebrovasc. Dis. 2001, 11 (Suppl. 1): 60-70.

Kawamata T., Dietrich W.D., Schallert T., Gotts J.E. et al. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction // Proc. Natl Acad. Sci USA. 1997, 94(15): 8179-84.

Schaebitz W.R., Schwab S., Spranger M., Hacke W. Intravascular brain derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats // J. Cereb. Blood Flow Metab. 1997, 17(5): 500-6.

Lin S.Z., Hoffer B.J., Kaplan P., Wang Y. Osteogenic protein-1 protects against cerebral infarction induced by MCA ligation in rats // Stroke. 1999, 30(1): 126-33.

Hartbauer M., Hutter-Paier B., Windisch M. Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons // J. Neural Transm. 2001, 108(5): 581-92.

Reinprecht I., Gschanes A., Windisch M., Fachbach G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats // Histochem. J. 1999, 31(6): 395-401.

Windholz E., Gschanes A., Windisch M., Fachbach G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 6-week-old rats // Histochem. J. 2000, 32(2):79-84.

Tatebayashi Y., Lee M.H., Li L., Iqbal K., Grundke-Iqbal I. The dentate gyrus neurogenesis: A therapeutic target for Alzheimer’s disease // Acta Neuropathol. 2003, 105(3): 225-32.

Zhang C., Chopp M., Cui Y. et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke // J. Neurosci. Res. 2010, 88(15): 3275-81.

Schwab M., Antonow-Schlorke I., Zwiener U., Bauer R. Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats // J. Neural Transm. Suppl. 1998, 53: 299-311.

Frey W. Treatment of Stroke with Intravenous and Intranasal Cerebrolysisn // Ebewe Pharma Res. Report, 2002: 1-22.

Ren J.M., Sietsma D., Qiu S., Moeesler H., Finklestein P. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats // Restorat. Neurol. Neurosci. 2007, 25(1): 25-31.

Maas A.I.R., Steyerberg E.W., Murray G.D., Bullock R., Baethmann A., Marshall L.F., Teasdale G.M. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations // Neurosurg. 1999, 44: 1286-98.

Golden Z., Golden C.J. Impact of brain injury severity on personality dysfunction // Int. J. Neurosci. 2003, 113(5): 733-45.

Conte V., Royo N.C., Shimizu S. et al. Neurotrophic factors: Pathophysiology and therapeutic applications in traumatic brain injury // Eur. J. Trauma. 2003, 29: 335-55.

Abdelaziz O.S., Elbanna Y.M., Elnaggar A.M., Mourad C.M. Effects of neuropeptide derivate FPF 1070 (cerebrolysin) administration on experimental acute spinal cord injury // Pan. Arab J. Neurosurg. 2007, 11: 51-61.

Haninec P., Dubovy P., Samal F., Houstava L., Stejskal L. Reinnervation of the rat musculocutaneous nerve stump after its direct reconnection with the C5 spinal cord segment by the nerve graft following avulsion of the ventral spinal roots: A comparison of intrathecal administration of brain-derived neurotrophic factor and Cerebrolysin // Exp. Brain Res. 2004, 159(4): 425-32.

Muresanu D.F. Cerebrolysin treatment efficacy study in middle cerebral artery ischemic stroke patients // Cerebrolysin — Therapeutical Effects in Vascular Dementia and Stroke. — Cluj-Napoca: Casa Cartii de Stiinta, 1999.

Hong Z., Zhu G-X., Chen H-B. et al. The clinical efficacy of Cerebrolysin in the treatment of acute ischemic stroke // Chin. J. Geriatr. Heart Brain Vessel Dis. 2005, 7: 331-3.

Skvortsova V.I., Stakhovskaia L.V., Gubskii L.V., Shamalov N.A., Tikhonova I.V., Smychkov A.S. A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke // Zh. Nevrol. Psikhiatr. im. S.S. Korsakova. 2004, 51-5.

Haffner Z., Javor L., Windisch M., Gmeinbauer R. Cerebrolysin in acute ischemic stroke. 31st Int Danube Symp. Neurological Sci. Continuing Ed. (Aug 25–29, Szeged, Hungary), 1999.

Lang W. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and cerebrolysin in acute ischemic stroke. Ebewe data on file, 2009.

Hong Z., Moessler H., Bornstein N., Brainin M., Heiss W.D., CASTA-Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia CASTA // Int. J. Stroke. 2009, 4(5): 406-12.

Heiss W.D., Brainin M., Bornstein N.M., Tuomilehto J., Hong Z., for the Cerebrolysin Acute Stroke Treatment in Asia (­CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: Results of a double-blind, placebo-controlled, randomized trial // Stroke. 2012, 43(3): 630-6.

Herrschaft H. Wirksamkeit von Cerebrolysin bei akutem ischamischem Hirninfarkt. Clinical study report. Interner Studienbericht Ebewe, 1998.

Ladurner G., Kalvach P., Mossler H.; Cerebrolysin Study Group. Neuroprotective treatment with Cerebrolysin in patients with acute stroke: A randomised controlled trial // J. Neural Transm. 2005, 112(3): 415-28.

Shamalov N.A., Stakhovskaia L.V., Burenchev D.V. et al. The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke // Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova. 2010, 110 (12, Pt. 2): 34-7.

Haffner Z., Gmeinbauer R., Moessler H. A randomized, double-blind, placebo-controlled trial with cerebrolysin in acute ischemic stroke // Cerebrovasc. Dis. 2001, 11(4): 76.

Shi Y., Shuju D. et al. Clinical studies with cerebrolysin in the treatment of acute cerebral hemorrhage // Chin. J. Nervous Mental Dis. 1990, 16: 228-30.

Bajenaru O., Tiu C., Moessler H., Antochi F., Muresanu D., Popescu B.O., Novak P. Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke // J. Med. Life. 2010, 3(2): 137-43.

Maksimova M., Briukhov V.V., Timerbaeva S.L. et al. Effectiveness of cerebrolysin in hypertensive supratentorial intracranial hemorrhages: Results of a randomized triple blind placebo-controled study // Zh. Nevrol. Psikhiatr. im. S.S. Korsakova. 2009, 109: 20-6.

Henry J.D., Phillips L.H., Cranfold J.R. et al. Theory of mind following traumatic brain injury: the role of emotion recognition and executive function // Neuropsychologica. 2006, 44:1623-8.

Sosin D.M., Sniezek J.E., Thurman D.J. Incidence of mild and moderate brain injury in the United States // Brain Inj. 1991, 10(1): 47-54.

Konig P., Wannders R., Witzmann A. et al. Cerebrolysin in traumatic brain injury — a pilot study of a neurotrophic and neurogenic agent in the treatment of acute traumatic brain injury // J. Neurol. Neurochirurgie Psychiatrie. 2006, 7: 12-20.

Kraus J.V., MacArthur D.L. Epidemiologic aspects of brain injury // Neurol. Clinics. 1996, 14: 435-50.

Greenspan A.I., Wrigley J.M., Kresnow M. et al. Factors influencing failure to return to work due to traumatic brain injury // Brain Inj. 1996, 10(3): 207-18.

Brooks A., Lindstrom J., McCray J. Cost of medical care for a population-based sample of persons surviving traumatic brain injury // J. Health Trauma. Rehabil. 1995, 10: 1-13.

Daniels J.P. Traumatic brain injury: Choosing drugs to assist recovery // Fam. Practice. 2006, 5: 5.

Zhou D., Yang S. Effect of cerebrolysin on acute brain injury patients // Zhong Hua Chuang Shang. 1993, 9: 289-90.

Feim Z., Yim S. Change of free radicals in the plasma of patients with craniocerebral trauma and therapeutical effect of cerebrolysin // Chinese J. Nervous Mental Dis. 1992, 18: 6-10.

He J., Fan J., Geng S. Efficacy of cerebrolysin in acute brain trauma // Chinese J. Clin. Practical Med. 2002, 4: 71-2.

Alvarez X.A., Sampedro C., Perez P. et al. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: An exploratory study // Int. Clin. Psychopharmacol. 2003, 18(5): 271-8.

Alvarez X.A., Sampedro C., Figueroa, J. et al. Reductions in qEEG slowing over 1 year an after treatment with cerebrolysin in patients with moderate-severe traumatic brain injury // J. Neural Transm. 2008, 115(5): 683-92.

Wong G.K.C., Zhu X.L., Poon W.S. Beneficial effect of cerebrolysin on moderate and severe head injury patients: Result of a cohort study // Acta Neurochir. 2005, 95 (Suppl.): 59-60.



  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг